BioMarin Pharmaceutical Inc. (BMRN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
BioMarin (BMRN) Q2 2026: Amicus Integration Unlocks $220M Synergy Path, Reshapes Rare Disease Platform
August 07, 2026
17
BMRN Q1 2026: Amicus Acquisition Adds $500M, Driving 20% Growth Trajectory Shift
May 05, 2026
24
BioMarin (BMRN) Q4 2025: Voxogo Surges 26% as Pipeline and Amicus Integration Set Up 2026 Inflection
February 25, 2026
21
BioMarin (BMRN) Q3 2025: Voxogo Hits $900M, Competition Shapes 2027 Scenario Range
October 27, 2025
24
BioMarin (BMRN) Q2 2025: Operating Cash Flow Jumps 55% as Pipeline and Portfolio Investments Accelerate
August 04, 2025
22
BioMarin (BMRN) Q1 2025: Operating Margin Expands 12 Points as Global Rare Disease Franchise Scales
July 04, 2025
BioMarin (BMRN) Q3 2024: Voxogo Drives 54% Revenue Growth, Accelerates Global Skeletal Franchise
October 29, 2024
BioMarin (BMRN) Q2 2024: Voxzogo Jumps 62% as Pipeline Focus Drives Margin Expansion
August 05, 2024
BMRN Q1 2024: Voxzogo Patient Base Expands by 500 as Indication Pipeline Accelerates
April 24, 2024
BioMarin (BMRN) Q4 2023: Voxogo Surges 178% as Pediatric Label Expansion Drives Uptake
February 22, 2024
22
BioMarin (BMRN) Q3 2023: Voxzogo Surges 165% as Roctavian Network Build Sets Up $3B Revenue Path
November 01, 2023
19
BioMarin (BMRN) Q2 2023: Voxzogo Guidance Raised 17% Amid Accelerated Patient Uptake and Roctavian Launch Momentum
July 31, 2023
BioMarin (BMRN) Q1 2023: Voxzogo Revenue Surges 140%, Offsetting Roctavian Launch Delays
April 26, 2023

Browse all companies